Stock Analiz

Alnylam Pharmaceuticals, Inc. (ALNY) stock forecast and price target

Price $165.04 · data as of November 13, 2026

12-month price target

Average target$299.96
Upside / downside+81.8%
Analysts27
ConsensusBuy
Low $180.00Average $299.96High $455.00

Gold marker: average target · white marker: today’s price ($165.04)

Analyst ratings

Strong buy 7Buy 14Hold 9Sell 0Strong sell 0

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends December 31, 2026
$22.68+346.5%$5.4B
Next fiscal year
ends December 31, 2027
$10.83−52.2%$6.5B
Next quarter
ends December 31, 2026
$2.42+93.7%$1.5B
Quarter after
ends March 31, 2027
$2.62+31.7%$1.5B

Consensus of the analysts covering Alnylam Pharmaceuticals, updated daily. In the last 30 days 11 estimates were raised and 0 lowered.

Our model vs. Wall Street

Analysts see 81.8% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Alnylam Pharmaceuticals’s intrinsic value about 34% above today’s market value, and it scores 2.4 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.

Frequently asked questions

What is the Alnylam Pharmaceuticals stock price target?

The average 12-month target from 27 analysts is $299.96, 81.8% above the current price of $165.04 Targets range from $180.00 to $455.00.

Is Alnylam Pharmaceuticals a buy according to analysts?

The consensus rating is “Buy” (7 strong buy, 14 buy, 9 hold). Ratings are opinions, not guarantees; this is not investment advice.

How much is Alnylam Pharmaceuticals expected to earn?

Analysts expect EPS of $22.68 for the fiscal year ending December 31, 2026 and $10.83 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.